MEP88208A - Leptomycin derivatives - Google Patents

Leptomycin derivatives

Info

Publication number: MEP88208A
Authority: ME; Montenegro
Prior art keywords: leptomycin derivatives; conjugates; leptomycin; derivatives; therapeutic use
Prior art date: 2006-06-09

Application number

MEP-882/08A

Other languages

Bosnian (bs)

English (en)

Croatian (hr)

Inventor

Herve Bouchard

Alain Commercon

Ravi V J Chari

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-09

Filing date

2007-05-23

Publication date

2011-12-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37311892&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP88208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-05-23 Application filed filed Critical

2011-12-20 Publication of MEP88208A publication Critical patent/MEP88208A/xx

Links

YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 title abstract 4
230000001225 therapeutic effect Effects 0.000 abstract 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 abstract 1
239000011230 binding agent Substances 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Cell Biology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pyrane Compounds (AREA)

MEP-882/08A 2006-06-09 2007-05-23 Leptomycin derivatives MEP88208A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06290948A EP1864682A1 (en)	2006-06-09	2006-06-09	Leptomycin derivatives
PCT/IB2007/001328 WO2007144709A2 (en)	2006-06-09	2007-05-23	Leptomycin derivatives

Publications (1)

Publication Number	Publication Date
MEP88208A true MEP88208A (en)	2011-12-20

Family

ID=37311892

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-882/08A MEP88208A (en)	2006-06-09	2007-05-23	Leptomycin derivatives

Country Status (29)

Country	Link
US (2)	US7816543B2 (xx)
EP (3)	EP1864682A1 (xx)
JP (1)	JP5162581B2 (xx)
KR (1)	KR20090018103A (xx)
CN (2)	CN101466409B (xx)
AR (1)	AR063668A1 (xx)
AU (1)	AU2007258896B2 (xx)
BR (1)	BRPI0712899A2 (xx)
CA (1)	CA2654322A1 (xx)
CL (1)	CL2007001648A1 (xx)
CR (1)	CR10459A (xx)
EA (1)	EA017345B1 (xx)
EC (1)	ECSP088936A (xx)
GT (1)	GT200800277A (xx)
HK (1)	HK1134240A1 (xx)
HN (1)	HN2008001788A (xx)
IL (1)	IL195419A0 (xx)
MA (1)	MA30689B1 (xx)
ME (1)	MEP88208A (xx)
MX (1)	MX2008015728A (xx)
MY (1)	MY148231A (xx)
NO (1)	NO20085127L (xx)
NZ (1)	NZ572947A (xx)
SG (2)	SG174067A1 (xx)
TN (1)	TNSN08463A1 (xx)
TW (1)	TWI411609B (xx)
UA (1)	UA95959C2 (xx)
WO (1)	WO2007144709A2 (xx)
ZA (1)	ZA200810015B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1864682A1 (en) *	2006-06-09	2007-12-12	Sanofi-Aventis	Leptomycin derivatives
EP1914242A1 (en)	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
CN101732308B (zh) *	2008-11-17	2011-11-30	中国人民解放军军事医学科学院毒物药物研究所	来普霉素b的新用途及含有它的药物组合物和产品
EP3100745B1 (en)	2009-02-05	2018-04-18	Immunogen, Inc.	Novel benzodiazepine derivatives
FR2947269B1 (fr)	2009-06-29	2013-01-18	Sanofi Aventis	Nouveaux composes anticancereux
FR2949469A1 (fr)	2009-08-25	2011-03-04	Sanofi Aventis	Derives anticancereux, leur preparation et leur application en therapeutique
UY32913A (es)	2009-10-02	2011-04-29	Sanofi Aventis	Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
EP2533810B1 (en)	2010-02-10	2016-10-12	ImmunoGen, Inc.	Cd20 antibodies and uses thereof
FR2963007B1 (fr)	2010-07-26	2013-04-05	Sanofi Aventis	Derives anticancereux, leur preparation et leur application therapeutique
MY183977A (en)	2011-02-15	2021-03-17	Immunogen Inc	Cytotoxic benzodiazepine derivatives
PL2872157T3 (pl)	2012-07-12	2020-07-13	Hangzhou Dac Biotech Co., Ltd	Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
GB201309807D0 (en) *	2013-05-31	2013-07-17	Pharma Mar Sau	Antibody drug conjugates
US20150148411A1 (en) *	2013-11-25	2015-05-28	The Rockefeller University	Compositions and methods for diagnosis and therapy of disorders related to alterations of myh9
JP6602834B2 (ja)	2014-06-30	2019-11-06	ターベダセラピューティクスインコーポレイテッド	標的化コンジュゲートならびにその粒子及び製剤
MA43345A (fr) *	2015-10-02	2018-08-08	Hoffmann La Roche	Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017075495A1 (en)	2015-10-28	2017-05-04	Tarveda Therapeutics, Inc.	Sstr-targeted conjugates and particles and formulations thereof
WO2017194568A1 (en)	2016-05-11	2017-11-16	Sanofi	Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
US10402527B2 (en)	2017-01-04	2019-09-03	Stmicroelectronics S.R.L.	Reconfigurable interconnect
JOP20190254A1 (ar)	2017-04-27	2019-10-27	Pharma Mar Sa	مركبات مضادة للأورام
WO2019030284A1 (en) *	2017-08-09	2019-02-14	Helmholtz-Zentrum für Infektionsforschung GmbH	NOVEL TARGETED CYTOTOXIC RATJADONE DERIVATIVES AND CONJUGATES THEREOF
US11531873B2 (en)	2020-06-23	2022-12-20	Stmicroelectronics S.R.L.	Convolution acceleration with embedded vector decompression

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4792522A (en)	1983-12-12	1988-12-20	Bristol-Myers Company	Rigolettone antitumor complex
US4625014A (en)	1984-07-10	1986-11-25	Dana-Farber Cancer Institute, Inc.	Cell-delivery agent
US4771070A (en)	1984-08-21	1988-09-13	Warner-Lambert Company	CL-1957A antibiotic compound
US4542225A (en)	1984-08-29	1985-09-17	Dana-Farber Cancer Institute, Inc.	Acid-cleavable compound
US4764368A (en)	1984-08-29	1988-08-16	Dana-Farber Cancer Institute, Inc.	Acid-cleavable compound
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2076465C (en)	1992-03-25	2002-11-26	Ravi V. J. Chari	Cell binding agent conjugates of analogues and derivatives of cc-1065
WO2001007013A2 (en) *	1999-07-22	2001-02-01	University Of Medicine And Dentistry Of New Jersey	Thioamide moiety-containing polymer drug conjugates
US7238525B2 (en)	2000-06-30	2007-07-03	The Regents Of The University Of California	Strategy for leukemia therapy
US20030091640A1 (en) *	2001-02-08	2003-05-15	Srinivasan Ramanathan	Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
EA010570B1 (ru)	2002-11-07	2008-10-30	Иммьюноджен, Инк.	Антитело к cd33 и способы его применения
KR101200133B1 (ko) *	2004-06-01	2012-11-13	제넨테크, 인크.	항체 약물 접합체 및 방법
US7446196B2 (en) *	2004-06-03	2008-11-04	Kosan Biosciences, Incorporated	Leptomycin compounds
US7541330B2 (en) *	2004-06-15	2009-06-02	Kosan Biosciences Incorporated	Conjugates with reduced adverse systemic effects
WO2006135371A1 (en) *	2005-06-09	2006-12-21	Kosan Biosciences Incorporated	Conjugates with reduced adverse systemic effects
EP1864682A1 (en) *	2006-06-09	2007-12-12	Sanofi-Aventis	Leptomycin derivatives

2006
- 2006-06-09 EP EP06290948A patent/EP1864682A1/en not_active Withdrawn
2007
- 2007-05-23 MX MX2008015728A patent/MX2008015728A/es active IP Right Grant
- 2007-05-23 ME MEP-882/08A patent/MEP88208A/xx unknown
- 2007-05-23 CA CA002654322A patent/CA2654322A1/en not_active Abandoned
- 2007-05-23 NZ NZ572947A patent/NZ572947A/en not_active IP Right Cessation
- 2007-05-23 AU AU2007258896A patent/AU2007258896B2/en not_active Ceased
- 2007-05-23 EA EA200870615A patent/EA017345B1/ru not_active IP Right Cessation
- 2007-05-23 EP EP07734635A patent/EP2032172B1/en active Active
- 2007-05-23 BR BRPI0712899-1A patent/BRPI0712899A2/pt not_active IP Right Cessation
- 2007-05-23 SG SG2011057817A patent/SG174067A1/en unknown
- 2007-05-23 JP JP2009513781A patent/JP5162581B2/ja not_active Expired - Fee Related
- 2007-05-23 MY MYPI20084971A patent/MY148231A/en unknown
- 2007-05-23 SG SG2011057809A patent/SG174066A1/en unknown
- 2007-05-23 UA UAA200900137A patent/UA95959C2/ru unknown
- 2007-05-23 CN CN2007800215355A patent/CN101466409B/zh not_active Expired - Fee Related
- 2007-05-23 EP EP11188684A patent/EP2540320A1/en not_active Withdrawn
- 2007-05-23 CN CN2012102164755A patent/CN102731611A/zh active Pending
- 2007-05-23 WO PCT/IB2007/001328 patent/WO2007144709A2/en active Search and Examination
- 2007-05-23 KR KR1020087029913A patent/KR20090018103A/ko active IP Right Grant
- 2007-05-24 TW TW096118553A patent/TWI411609B/zh not_active IP Right Cessation
- 2007-06-07 CL CL2007001648A patent/CL2007001648A1/es unknown
- 2007-06-08 AR ARP070102511A patent/AR063668A1/es not_active Application Discontinuation
2008
- 2008-11-17 TN TNP2008000463A patent/TNSN08463A1/en unknown
- 2008-11-20 IL IL195419A patent/IL195419A0/en unknown
- 2008-11-24 US US12/276,568 patent/US7816543B2/en not_active Expired - Fee Related
- 2008-11-25 ZA ZA2008/10015A patent/ZA200810015B/en unknown
- 2008-11-25 CR CR10459A patent/CR10459A/es not_active Application Discontinuation
- 2008-12-03 EC EC2008008936A patent/ECSP088936A/es unknown
- 2008-12-08 GT GT200800277A patent/GT200800277A/es unknown
- 2008-12-09 HN HN2008001788A patent/HN2008001788A/es unknown
- 2008-12-09 NO NO20085127A patent/NO20085127L/no not_active Application Discontinuation
- 2008-12-26 MA MA31515A patent/MA30689B1/fr unknown
2009
- 2009-12-10 HK HK09111635.9A patent/HK1134240A1/xx not_active IP Right Cessation
2010
- 2010-09-14 US US12/881,792 patent/US20110002947A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1134240A1 (en)	2010-04-23
CN101466409B (zh)	2012-11-21
GT200800277A (es)	2009-06-16
CA2654322A1 (en)	2007-12-21
AU2007258896B2 (en)	2013-01-24
EA200870615A1 (ru)	2009-04-28
US20090182038A1 (en)	2009-07-16
MX2008015728A (es)	2009-01-09
MY148231A (en)	2013-03-29
JP2009539820A (ja)	2009-11-19
SG174066A1 (en)	2011-09-29
CL2007001648A1 (es)	2008-01-18
MA30689B1 (fr)	2009-09-01
EP2540320A1 (en)	2013-01-02
BRPI0712899A2 (pt)	2013-01-08
US7816543B2 (en)	2010-10-19
CR10459A (es)	2009-01-09
US20110002947A1 (en)	2011-01-06
AU2007258896A1 (en)	2007-12-21
TWI411609B (zh)	2013-10-11
AR063668A1 (es)	2009-02-11
UA95959C2 (xx)	2011-09-26
HN2008001788A (es)	2012-08-27
WO2007144709A3 (en)	2008-06-12
EA017345B1 (ru)	2012-11-30
KR20090018103A (ko)	2009-02-19
JP5162581B2 (ja)	2013-03-13
SG174067A1 (en)	2011-09-29
IL195419A0 (en)	2009-08-03
EP2032172B1 (en)	2012-06-06
CN102731611A (zh)	2012-10-17
TW200812996A (en)	2008-03-16
EP2032172A2 (en)	2009-03-11
TNSN08463A1 (en)	2010-04-14
WO2007144709A2 (en)	2007-12-21
ZA200810015B (en)	2010-02-24
ECSP088936A (es)	2009-01-30
NZ572947A (en)	2011-12-22
EP1864682A1 (en)	2007-12-12
NO20085127L (no)	2009-01-08
CN101466409A (zh)	2009-06-24

Publication	Publication Date	Title
MEP88208A (en)	2011-12-20	Leptomycin derivatives
IL283205A (en)	2021-06-30	Attached medicinal substance that binds to cells, preparations containing them and their uses
CR20150097A (es)	2015-04-14	Composición inmunogénica
EA201290506A1 (ru)	2013-03-29	Частицы для доставки множества агентов
CR11454A (es)	2010-06-28	Derivados de isoxazolo-piridina
IL208937A0 (en)	2011-01-31	Cell binding agent cytotoxic drug conjugates, compositions comprising the same and uses thereof
MX2009004664A (es)	2009-10-12	Inmunoglobulinas hibridas con partes moviles.
EA201290838A1 (ru)	2013-05-30	Конъюгаты пирролбензодиазепина направленного действия
HN2008000188A (es)	2010-11-09	7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
NZ600039A (en)	2013-11-29	Biocompatible biodegradable fumagillin analog conjugates
MX2013005046A (es)	2013-12-12	Agentes citotoxicos que comprenden nuevos derivados de ansamitocina.
ECSP088759A (es)	2008-10-31	Composiciones farmacéuticas
NZ603939A (en)	2013-08-30	Conjugated blood coagulation factor viii
MX2011011380A (es)	2012-02-21	Eficiencia aumentada de composiciones de protección solar.
GT200600097A (es)	2006-11-13	Formas farmaceuticas con propiedades farmacocineticas mejoradas
NZ603938A (en)	2013-08-30	Conjugated blood coagulation factor viia
CR9114A (es)	2008-01-21	2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
MX2009006410A (es)	2009-06-23	Conjugados de polimero-oligonucleotido, proteina y/o peptido.
EA201170821A1 (ru)	2011-12-30	Энзастаурин для лечения рака
PE20142325A1 (es)	2015-02-01	Composiciones derivadas de la quitosana
RS52461B (en)	2013-02-28	FLUPENTIKSOL COMPOSITIONS
IL208567A0 (en)	2010-12-30	Oligomer-aryloxy-substituted propanamine conjugates, compositions comprising the same and uses thereof
ECSP10010398A (es)	2010-09-30	Composiciones agrícolas
UY30368A1 (es)	2008-01-02	2-alcoxi-3,4,5-trihidroxi-alquilamida-benzazepinas, su preparacion, composiciones que las contienen y utilizacion
CO6541608A2 (es)	2012-10-16	Formulación de empaque para evitar la insolubilidad de las composiciones que contienen quitosán